Athena Athena

X
[{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Ritter Pharmaceuticals","sponsor":"Qualigen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Ritter Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Qualigen offers a number of revenue-generating therapeutic and diagnostic products that may help Ritter Pharmaceuticals to advance its pipeline and grow its business.

            Lead Product(s): AS1411

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Qualigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger April 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.

            Lead Product(s): Galacto-oligosaccharide

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Qualigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger January 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY